Ivabradine: Bridging Molecular Mechanisms and Clinical Practice in Cardiac Care

Ivabradine, a medication that selectively lowers heart rate by inhibiting the funny current (If) in the sinus node, has shown significant potential in managing various cardiac conditions. It has unique properties as a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker, primarily used in cardiology and cardiovascular medicine. It is primarily employed to lower heart rate in chronic stable angina, heart failure, and inappropriate sinus tachycardia. Ivabradine’s unique mechanism selectively reduces heart rate without affecting contractility or blood pressure, making it valuable, especially for patients who cannot tolerate β-blockers due to comorbidities. Indeed, it effectively reduces the occurrence of angina attacks and the need for short-acting nitrates, maintaining its anti-anginal benefits over the long term. This review provides insights into Ivabradine’s molecular mechanism, efficacy, clinical manifestation, and potential future applications in managing various cardiovascular conditions.